DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 37 · March 2004 DOI: 10.1055/s-002-3251

Original Paper

43
Schneider, B.; Weigmann, H.; Hiemke, C.; Weber, B.; Fritze, J.: Reduction Of Clozapine-Induced Hypersalivation By Pirenzepine Is Safe
46
Juckel, G.; Mavrogiorgou, P.; Bredemeier, S.; Gallinat, J.; Frodl, T.; Schulz, C.; Möller, H.-J.; Hegerl, U.: Loudness Dependence of Primary Auditory-Cortex-Evoked Activity as Predictor of Therapeutic Outcome to Prophylactic Lithium Treatment in Affective Disorders - A Retrospective Study
52
Reznik, I.; Yavin, I.; Stryjer, R.; Spivak, B.; Gonen, N.; Strous, R.; Mester, R.; Weizman, A.; Kotler, M.: Clozapine in the Treatment of Obsessive-compulsive Symptoms in Schizophrenia Patients: A Case Series Study
57
Nisijima, K.; Shioda, K.; Yoshino, T.; Takano, K.; Kato, S.: Memantine, an NMDA Antagonist, Prevents the Development of Hyperthermia in an Animal Model for Serotonin Syndrome
63
Bergemann, N.; Frick, A.; Parzer, P.; Kopitz, J.: Olanzapine Plasma Concentration, Average Daily Dose, and Interaction with Co-Medication in Schizophrenic Patients
69
LLerena, Adrián; de la Rubia, Alfredo; Berecz, Roland; Dorado, Pedro: Relationship between Haloperidol Plasma Concentration, Debrisoquine Metabolic Ratio, CYP2D6 and CYP2C9 Genotypes in Psychiatric Patients
81
Siepmann, M.; Handel, J.; Mueck-Weymann, M.; Kirch, W.: The Effects of Moclobemide on Autonomic and Cognitive Functions in Healthy Volunteers

Original Paper

74
Bajbouj, M.; Gallinat, J.; Niehaus, L.; Lang, U. E.; Roricht, S.; Meyer, B.-U.: Abnormalities of Inhibitory Neuronal Mechanisms in the Motor Cortex of Patients with Schizophrenia

Letter

88
Dietrich, D. E.; Gödecke-Koch, T.; Richter-Witte, C.; Emrich, H. M.: Lamotrigine in the Treatment of Confusion Psychosis
90
Hermann, D.; Heinz, A.; Croissant, B.; Mann, K.: Serotonin Reuptake Inhibitor Provoked Recurrence of Alcohol Hallucinosis - Remission with Additive Amisulpride Medication